These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 11020574)

  • 1. Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy.
    Smith RS; Kapp DS; Chen Q; Teng NN
    Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):767-78. PubMed ID: 11020574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.
    Sood BM; Jones J; Gupta S; Khabele D; Guha C; Runowicz C; Goldberg G; Fields A; Anderson P; Vikram B
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):208-16. PubMed ID: 12909235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten-year outcome including patterns of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma.
    Stewart KD; Martinez AA; Weiner S; Podratz K; Stromberg JS; Schray M; Mitchell C; Sherman A; Chen P; Brabbins DA
    Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):527-35. PubMed ID: 12243832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?
    Kwon JS; Abrams J; Sugimoto A; Carey MS
    Int J Gynecol Cancer; 2008; 18(4):820-4. PubMed ID: 17892450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation.
    Martinez AA; Weiner S; Podratz K; Armin AR; Stromberg JS; Stanhope R; Sherman A; Schray M; Brabbins DA
    Gynecol Oncol; 2003 Sep; 90(3):537-46. PubMed ID: 13678721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy.
    Turner BC; Knisely JP; Kacinski BM; Haffty BG; Gumbs AA; Roberts KB; Frank AH; Peschel RE; Rutherford TJ; Edraki B; Kohorn EI; Chambers SK; Schwartz PE; Wilson LD
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):77-84. PubMed ID: 9422561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma.
    Hamilton CA; Cheung MK; Osann K; Balzer B; Berman ML; Husain A; Teng NN; Kapp DS; Chan JK
    Gynecol Oncol; 2006 Nov; 103(2):679-83. PubMed ID: 16793126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
    Murphy KT; Rotmensch J; Yamada SD; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1272-6. PubMed ID: 12654437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer.
    Townamchai K; Berkowitz R; Bhagwat M; Damato AL; Friesen S; Lee LJ; Matulonis U; O'Farrell D; Viswanathan AN
    Gynecol Oncol; 2013 Apr; 129(1):18-21. PubMed ID: 23262378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium.
    Creasman WT; Kohler MF; Odicino F; Maisonneuve P; Boyle P
    Gynecol Oncol; 2004 Dec; 95(3):593-6. PubMed ID: 15581969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival.
    Carcangiu ML; Chambers JT
    Int J Gynecol Pathol; 1995 Jan; 14(1):30-8. PubMed ID: 7883423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
    Fields AL; Einstein MH; Novetsky AP; Gebb J; Goldberg GL
    Gynecol Oncol; 2008 Jan; 108(1):201-6. PubMed ID: 17997145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of management on the prognosis of pure uterine papillary serous cancer - a Taiwanese Gynecologic Oncology Group (TGOG) study.
    Huang CY; Tang YH; Chiang YC; Wang KL; Fu HC; Ke YM; Lau HY; Hsu KF; Wu CH; Cheng WF
    Gynecol Oncol; 2014 May; 133(2):221-8. PubMed ID: 24556064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression.
    Nordström B; Strang P; Lindgren A; Bergström R; Tribukait B
    Anticancer Res; 1996; 16(2):899-904. PubMed ID: 8687148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uterine Papillary Serous Carcinoma: A Single-Institution Review of 62 Cases.
    Black C; Feng A; Bittinger S; Quinn M; Neesham D; McNally O
    Int J Gynecol Cancer; 2016 Jan; 26(1):133-40. PubMed ID: 26588230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival Differences Among Uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial Cancers: A National Cancer Database Analysis.
    McGunigal M; Liu J; Kalir T; Chadha M; Gupta V
    Int J Gynecol Cancer; 2017 Jan; 27(1):85-92. PubMed ID: 27759595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer.
    Barney BM; Petersen IA; Mariani A; Dowdy SC; Bakkum-Gamez JN; Haddock MG
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):109-15. PubMed ID: 22543202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
    Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
    Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC).
    Fader AN; Starks D; Gehrig PA; Secord AA; Frasure HE; O'Malley DM; Tuller ER; Rose PG; Havrilesky LJ; Moore KN; Huh WK; Axtell AE; Kelley JL; Zanotti KM;
    Gynecol Oncol; 2009 Nov; 115(2):244-8. PubMed ID: 19712966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Survival Outcomes of Uterine Papillary Serous Carcinoma, Clear Cell Carcinoma, Grade 3 Endometrioid Adenocarcinoma, and Carcinosarcoma of Endometrial Cancer in Rajavithi Hospital.
    Prueksaritanond N; Chantape W
    J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S75-83. PubMed ID: 27266220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.